PanagenehasdevelopedPNAs™miRNAinhibitorsthataresuperiorinspecificityandstABIlitytoexistingmiRNAinhibitors,usingPNA’sadvantages.PNAs™miRNAinhibitorsaresinglestrandedPNAs,whichareanexcellenttoolforstudyingthefunctionofmiRNAsbyspecificallybindingtoendogenousmiRNAsandeffectivelyinhibitingtheirfunctionInaddition,PNAs™miRNAinhibitorsarecombinedwithCPP(CellPenetratingPeptide),sothattransfectionefficiencycanbeincreasedanditispossIBLetopenetrateitevenwithouttransfectionreagentincertaintypesofcells. Panagene的PNAClamp™突变检测试剂盒布拉夫在包括甲状腺癌，恶性黑色素瘤，卵巢癌，结直肠癌在内的几种癌症中发现了BRAF突变。对于甲状腺癌，有40多种不同类型的BRAF突变。在这些突变中，外显子15上的V600E突变（最重要的是频率超过90％）最为重要，即第1799个碱基的核苷酸从T变为A，导致氨基酸从缬氨酸变为谷氨酸。尤其是，用约2,000 bp检测到BRAF V600E突变。甲状腺乳头状癌的频率为45％，被认为是甲状腺癌的预后指标。